Group 1 - The company announced that its subsidiary, Anhui Dehe Pawn Co., Ltd., has provided a maximum collateral guarantee of 23 million RMB to China Everbright Bank Co., Ltd. for a credit facility [2][6] - The internal decision-making process for this guarantee did not require approval from the company's board of directors or shareholders, as it complied with relevant regulations [3] - The guarantee is intended to support the company's daily operations and business development, aligning with its overall interests and development plans [8] Group 2 - As of the announcement date, the total amount of external guarantees provided by the company and its subsidiaries is 942.7004 million RMB, which represents 88.89% of the company's most recent audited net assets [8] - The company has not provided guarantees for its controlling shareholders or related parties, and there are currently no overdue guarantees or litigation related to guarantees [8]

证券代码：688709 证券简称：成都华微 公告编号：2026-008 成都华微电子科技股份有限公司 鉴于王源先生的离任将导致公司独立董事人数少于董事会成员人数的三分之一，根据《中华人民共和国 公司法》（以下简称"《公司法》"）《上市公司独立董事管理办法》《上海证券交易所科创板上市公司 自律监管指引第1号一一规范运作》以及《公司章程》等相关规定，王源先生的辞职报告将自公司股东 会选举产生新任独立董事后生效。在此之前，王源先生将按照有关法律法规的规定继续履行独立董事及 董事会各专门委员会委员的职责。截至本公告披露日，王源先生未持有公司股份，亦不存在应当履行而 未履行的承诺事项。 为保证公司董事会的规范运作，根据《公司法》《公司章程》等相关规定，经公司第二届董事会提名委 员会进行任职资格审查，认为张万里先生符合《公司法》《上市公司独立董事管理办法》等相关法律法 规、部门规章、规范性文件和《公司章程》规定的独立董事任职条件，不存在中国证监会以及上海证券 交易所规定的不得担任独立董事的情形。公司董事会同意提名张万里先生为公司第二届董事会独立董事 候选人（简历详见附件）。任期自股东会审议通过之日起，至第二届董事会任期届 ...

证券代码：600025 证券简称：华能水电 公告编号：2026-003 华能澜沧江水电股份有限公司 2026年度第二期科技创新债券和 第二期绿色科技创新债券（乡村振兴）发行公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 2026年2月12日 华能澜沧江水电股份有限公司（以下简称公司）已于近日完成了2026年度第二期科技创新债券和第二期 绿色科技创新债券（乡村振兴）的发行，发行额分别为人民币10亿元、10亿元，发行利率分别为 1.58%、1.61%，期限分别为95天、177天，单位面值均为100元人民币。本次发行完成后，公司短期融 资券（含超短期融资券）余额为人民币76亿元，中期票据（含永续中票）余额为人民币160亿元。2026 年度第二期科技创新债券由中国银行作为牵头主承销商、农业银行作为联席主承销商，第二期绿色科技 创新债券（乡村振兴）由中国建设银行作为牵头主承销商、中国银行作为联席主承销商，通过簿记建 档、集中配售的方式在全国银行间债券市场公开发行，债券募集资金将用于偿还带息负债。债券发行的 有关文件已在中国货币网和 ...

Core Viewpoint - The company has approved the addition of implementation entities and locations for certain fundraising projects, along with adjustments to the internal investment structure, to enhance the efficiency of fundraising and ensure the smooth progress of projects [1][8][14]. Group 1: Board Meeting Details - The 11th meeting of the 4th Board of Directors was held on February 11, 2026, with all 9 directors present, and the meeting was conducted in accordance with legal and regulatory requirements [1][4]. - The board unanimously approved the proposal regarding the addition of implementation entities and locations for fundraising projects [4][14]. Group 2: Fundraising Project Adjustments - The company has decided to add its wholly-owned subsidiaries, Dongguan Jundingda New Materials Technology Co., Ltd. and Suzhou Jundingda New Materials Technology Co., Ltd., as joint implementation entities for the "Research and Development Center and Information Technology Construction Project" [1][10]. - The project locations have been expanded to include Dongguan and Suzhou, enhancing the operational capacity of the fundraising projects [1][10]. Group 3: Financial Details - The company raised a total of RMB 558.2 million from the public offering of 10 million shares at a price of RMB 55.82 per share, with net proceeds amounting to RMB 484.0668 million after deducting various fees [8][9]. - The funds have been verified by Tianjian Accounting Firm, ensuring compliance with regulatory standards [8][9]. Group 4: Internal Investment Structure Adjustments - The internal investment structure for the fundraising project has been adjusted to optimize resource allocation and improve the efficiency of fund usage, including reductions in renovation and equipment costs [12][14]. - The adjustments are based on actual project implementation progress and market conditions, ensuring that the total investment amount and core purposes remain unchanged [12][14]. Group 5: Compliance and Oversight - The company adheres to relevant regulations regarding fundraising management, ensuring that funds are used legally and effectively [13][15]. - The sponsor institution, CITIC Securities, has confirmed that the adjustments made by the company do not harm the interests of shareholders, particularly minority shareholders [15][17].

股票代码：601233 股票简称：桐昆股份 公告编号：2026-009 桐昆集团股份有限公司关于 2026年度第一期科技创新债券发行结果的公告 本期发行科创债的相关文件已在中国货币网(www.chinamoney.com.cn)和上海清算所网站 (www.shclearing.com）上刊登。 特此公告。 桐昆集团股份有限公司董事会 2026年2月12日 2024年4月25日，桐昆集团股份有限公司（以下简称"桐昆股份"或"公司"）第九届董事会第八次会议审 议通过了《关于发行超短期融资券的议案》，上述议案经2024年5月21日召开的公司2023年年度股东大 会审议批准。股东大会同意公司向中国银行间市场交易商协会（以下简称"交易商协会"）申请注册发行 不超过60亿元（人民币，下同）的超短期融资券，并授权董事会办理发行的具体事项。 2024年8月30日，经交易商协会《接受注册通知书》（中市协注［2024］SCP273号）核准，交易商协会 决定接受公司超短期融资券注册，注册金额为人民币60亿元。注册额度自通知书发出之日起2年内有 效，公司在注册有效期内可分期发行超短期融资券。 2026年2月9日，公司在全国银行间市场 ...

Core Viewpoint - The company plans to utilize part of its temporarily idle raised funds for cash management, ensuring that it does not affect the normal investment plan and guarantees fund safety [2]. Group 1: Cash Management Plan - The company intends to use up to RMB 200,000,000 (including principal) of idle raised funds for cash management, focusing on high-security, good liquidity, and capital preservation bank deposit products [2]. - The cash management products may include but are not limited to agreement deposits, time deposits, and large-denomination certificates of deposit, with a maximum term of 12 months [2]. - This cash management plan does not require submission for shareholder meeting approval [2]. Group 2: Current Status of Cash Management - As of the announcement date, the company has a remaining balance of RMB 54,000,000 from the temporarily idle raised funds used for cash management [2]. - The highest daily balance and usage period of the idle raised funds for cash management have not exceeded the authorization range set by the company's board of directors [2].

登录新浪财经APP 搜索【信披】查看更多考评等级 股票简称：紫光股份 股票代码：000938 公告编号：2026－010 紫光股份有限公司 关于2026年度向特定对象发行A股股票摊薄即期回报、 填补措施及相关主体承诺的公告 本公司及董事会全体成员保证信息披露的内容真实、准确和完整，没有虚假记载、误导性陈述或重大遗 漏。 本公告中如无特别说明，相关用语具有与《紫光股份有限公司2026年度向特定对象发行A股股票预案》 中相同的含义。 紫光股份有限公司（以下简称"公司"）于2026年2月11日召开的公司第九届董事会第二十次会议审议通 过了公司2026年度向特定对象发行A股股票（以下简称"本次发行"）的相关议案。根据《国务院关于进 一步促进资本市场健康发展的若干意见》（国发[2014]17号）、《国务院办公厅关于进一步加强资本市 场中小投资者合法权益保护工作的意见》（国办发[2013]110号）和《关于首发及再融资、重大资产重 组摊薄即期回报有关事项的指导意见》（中国证券监督管理委员会公告[2015]31号）的相关规定，为保 障中小投资者知情权，维护中小投资者利益，公司就本次向特定对象发行A股股票相关事项对即期回报 ...

证券代码：000876 证券简称：新希望 公告编号：2026-15 债券代码：127049 债券简称：希望转2 新希望六和股份有限公司 第十届董事会第十一次会议决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确、完整，没有虚假 记载、误导性陈述或重大 遗漏。 登录新浪财经APP 搜索【信披】查看更多考评等级 一、董事会会议召开情况 具体内容详见公司于2026年2月12日在巨潮资讯网（www.cninfo.com.cn）披露的《关于调整向特定对象 发行股票募集资金投资项目经济效益测算的公告》。 （二）审议通过了"关于公司向特定对象发行A股股票方案的论证分析报告（第三次修订稿）的议案" 新希望六和股份有限公司（以下简称"公司"）第十届董事会第十一次会议通知于2026年2月10日以电子 邮件方式通知了全体董事。第十届董事会第十一次会议于2026年2月11日以通讯表决方式召开。本次会 议应参加表决董事9人，实际表决董事9人，会议的召开及表决程序符合有关法律、行政法规、部门规 章、规范性文件和公司《章程》的规定，所作决议合法有效。 二、董事会会议审议情况 本次会议由董事以传真方式会签，审议并通过了如下议案： ...

Group 1 - The company held its first extraordinary general meeting of shareholders on February 11, 2026, in Guangzhou, with no resolutions being rejected [2] - The meeting was convened by the board of directors and chaired by Mr. Zhang Shixi, using a combination of on-site and online voting methods, complying with relevant laws and regulations [2][3] - The company successfully elected independent directors to the second board of directors during the meeting [4][5] Group 2 - Mr. Zhang Shixi submitted his resignation as general manager due to work adjustments, effective immediately upon delivery to the board [9] - The board appointed Mr. Chen Jianxu as the new general manager, with a term lasting until the end of the current board's term [9][12] - Mr. Chen Jianxu has a background in the pharmaceutical industry and has held various positions in reputable companies, ensuring his qualifications meet legal and regulatory requirements [13][14] Group 3 - The company plans to publicly transfer part of its accounts receivable held by a subsidiary through the Hunan United Property Exchange [15][16] - The total accounts receivable to be transferred amounts to 489.784 million yuan, with a provision for bad debts of 459.7945 million yuan, resulting in a book value of 29.9895 million yuan [17][20] - The transaction aims to optimize the company's asset structure and improve liquidity, with the final transaction price to be determined through public bidding [27][24]

Core Viewpoint - Chengdu Shengnuo Biotechnology Co., Ltd. announced its participation in the national organized procurement of pharmaceuticals, with several products expected to be selected for the new round of procurement, which is a significant step for the company in expanding its market presence and enhancing competitiveness in the peptide pharmaceutical market [1][2]. Group 1: Selected Products - The company’s subsidiary, Chengdu Shengnuo Pharmaceutical Co., Ltd., participated in the national organized procurement for the first to eighth batches, with products such as Acetate Octreotide Injection and Acetate Atosiban Injection expected to be selected [1]. - The selected products include Acetate Octreotide Injection (seventh batch), Acetate Atosiban Injection (eighth batch), Somatostatin Injection (eighth batch), Thymosin Alpha 1 Injection, and Eptifibatide Injection [1]. Group 2: Impact on the Company - The selected products are expected to enhance the company's sales revenue significantly in 2024 and the first nine months of 2025, with the procurement cycle running until the end of 2028 [2]. - The procurement will prioritize the use of selected drugs in medical institutions, ensuring the completion of the agreed procurement volume, which is expected to positively impact the company's operational development [2]. - The selection also reflects the stability and reliability of the company's drug quality, which is crucial for its competitive position in the peptide pharmaceutical market [2].